Top Markets
Coin of the day
Clarus Therapeutics Holdings, Inc. Clarus Therapeutics Holdings, Inc.

Clarus Therapeutics Holdings, Inc.

CRXTQ
株式のランク #40846
Clarus Therapeutics Holdings, Inc. is a pharmaceutical enterprise dedicated to... Clarus Therapeutics Holdings, Inc. is a pharmaceutical enterprise dedicated to developing and marketing oral testosterone replacement therapies across the United States. Its primary offering is JATENZO, an oral soft gel formulation of testosterone undecanoate, prescribed for men suffering from hypogonadism. The company has also entered into licensing agreements, including one with HavaH Therapeutics for androgen treatments targeting inflammatory breast disease and specific types of breast cancer. Additionally, Clarus holds an agreement with The Royal Institution for the Advancement of Learning/McGill University to advance and commercialize McGill's exclusive technology, which is designed to address human conditions associated with CoQ10 deficiencies. Founded in 2003, Clarus Therapeutics Holdings, Inc. is headquartered in Northbrook, Illinois. On September 5, 2022, the company, along with an affiliate, voluntarily sought reorganization under Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware.
株価
$0.0014
最終同期: 2023-02-28
時価総額
$72.83K
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 Clarus Therapeutics Holdings, Inc. (CRXTQ)

カテゴリー

Clarus Therapeutics Holdings, Inc.(CRXTQ)の発行済株式数
August 2026 時点の発行済株式数 0
Clarus Therapeutics Holdings, Inc. の最新の財務報告および株価によると、現在の発行済株式数は 0 です。August 2026 の終わりには、同社は 0 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Clarus Therapeutics Holdings, Inc.(CRXTQ)の発行済株式数の履歴(2026 ~ 2026)
各年末時点の発行済株式数
発行済株式数 変化
提供された日付のデータは十分ではありません。
類似企業や競合他社の発行済株式数
企業 発行済株式数
892.40M -
US
2.44B -
US
1.77B -
US
796.00M -
CH
0.00 -
US